Stereotaxis, Inc.

Stereotaxis markets its products in the U.S., Europe, and the rest of the world through direct sales and channel partners. The business is geographically important because system placements, regulatory approvals, and clinical adoption can vary significantly by region, affecting where the installed base and recurring device demand develop. Its APT catheter manufacturing footprint is based in Rogers, Minnesota, while corporate headquarters are in St. Louis, Missouri.

The business depends on regulatory approvals, clinical adoption, and successful conversion of backlog into revenue, all of which can be slow and uncertain in medical devices. It also faces competition from robotic navigation, imaging, and traditional catheter companies, while sales execution depends on access to hospitals, physician support, and distributor performance. Because products are sold into regulated procedures, revenue recognition, inventory, warranty, and acquisition-related estimates can materially affect reported results.